Drug Profile


Alternative Names: 1014802; [14C]-BIIB 074; BIIB 074; CNV 1014802; GSK1014802

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Biogen; GlaxoSmithKline
  • Class Analgesics; Neuropsychotherapeutics; Pyrrolidines; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Neuropathic pain; Trigeminal neuralgia

Highest Development Phases

  • Phase II Erythromelalgia; Neuropathic pain; Trigeminal neuralgia
  • Discontinued Bipolar disorders

Most Recent Events

  • 31 Oct 2016 Biogen plans a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02951221)
  • 01 Aug 2016 Biogen initiates a phase I pharmacokinetics trial for Trigeminal neuralgia (In volunteers) in United Kingdom (PO) (NCT02831517)
  • 12 Jul 2016 Convergence Pharmaceuticals plans a phase II extension trial for Neuropathic pain in United Kingdom (UKCRN30092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top